Cadrenal Therapeutics (NASDAQ:CVKD) CEO Quang Pham Sells 2,581 Shares

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) CEO Quang Pham sold 2,581 shares of Cadrenal Therapeutics stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $13.99, for a total transaction of $36,108.19. Following the completion of the transaction, the chief executive officer directly owned 210,723 shares in the company, valued at approximately $2,948,014.77. The trade was a 1.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Cadrenal Therapeutics Stock Down 1.2%

Shares of NASDAQ CVKD opened at $14.03 on Friday. Cadrenal Therapeutics, Inc. has a 52 week low of $8.74 and a 52 week high of $22.90. The firm’s fifty day moving average is $12.34 and its 200 day moving average is $14.13. The company has a market cap of $28.72 million, a price-to-earnings ratio of -1.58 and a beta of 0.95.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its earnings results on Monday, August 11th. The company reported ($1.87) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.27). Equities research analysts anticipate that Cadrenal Therapeutics, Inc. will post -7.59 earnings per share for the current year.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.